These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

756 related items for PubMed ID: 19555131

  • 1. When oral agents fail: optimizing insulin therapy in the older adult.
    Meece J.
    Consult Pharm; 2009 Jun; 24 Suppl B():11-7. PubMed ID: 19555131
    [Abstract] [Full Text] [Related]

  • 2. Minimizing the risk of hypoglycemia in older adults: a focus on long-term care.
    Garza H.
    Consult Pharm; 2009 Jun; 24 Suppl B():18-24. PubMed ID: 19555132
    [Abstract] [Full Text] [Related]

  • 3. Recognizing the rising impact of diabetes in seniors and implications for its management.
    Drab SR.
    Consult Pharm; 2009 Jun; 24 Suppl B():5-10. PubMed ID: 19555130
    [Abstract] [Full Text] [Related]

  • 4. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK.
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [Abstract] [Full Text] [Related]

  • 5. Transitioning and adjusting insulin analog therapy in elderly patients.
    Bray B.
    Consult Pharm; 2008 Apr; 23 Suppl B():17-23. PubMed ID: 18540789
    [Abstract] [Full Text] [Related]

  • 6. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 7. Managing older adults with diabetes.
    Hainer TA.
    J Am Acad Nurse Pract; 2006 Jul; 18(7):309-17. PubMed ID: 16827836
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A, Borot S, Raccah D.
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [Abstract] [Full Text] [Related]

  • 9. Type 2 diabetes mellitus--guidelines for initiating insulin therapy.
    Yeap BB.
    Aust Fam Physician; 2007 Jul; 36(7):549-53. PubMed ID: 17619673
    [Abstract] [Full Text] [Related]

  • 10. Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient.
    Meneghini L.
    Int J Clin Pract; 2008 Aug; 62(8):1255-64. PubMed ID: 18705822
    [Abstract] [Full Text] [Related]

  • 11. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 12. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
    Robertson C.
    Diabetes Educ; 2006 Jun; 32(3):423-32. PubMed ID: 16772658
    [Abstract] [Full Text] [Related]

  • 13. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
    Efendic S, Alvarsson M, Brismar K, Wagner H.
    Acta Physiol (Oxf); 2008 Jan; 192(1):117-25. PubMed ID: 18171434
    [Abstract] [Full Text] [Related]

  • 14. An overview of incretin clinical trials.
    Garber AJ, Spann SJ.
    J Fam Pract; 2008 Sep; 57(9 Suppl):S10-8. PubMed ID: 18786339
    [Abstract] [Full Text] [Related]

  • 15. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 16. Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.
    Mathieu C, Bollaerts K.
    Int J Clin Pract Suppl; 2007 Aug; (154):29-37. PubMed ID: 17593275
    [Abstract] [Full Text] [Related]

  • 17. Pharmacologic management of the older patient with type 2 diabetes mellitus.
    Neumiller JJ, Setter SM.
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):324-42. PubMed ID: 20129254
    [Abstract] [Full Text] [Related]

  • 18. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M, Rayfield EJ.
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [Abstract] [Full Text] [Related]

  • 19. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK.
    J Am Pharm Assoc (2003); 2009 Jun; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [Abstract] [Full Text] [Related]

  • 20. Management of type 2 diabetes: oral agents, insulin, and injectables.
    Fonseca VA, Kulkarni KD.
    J Am Diet Assoc; 2008 Apr; 108(4 Suppl 1):S29-33. PubMed ID: 18358251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.